Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
MannKind ( (MNKD) ) has provided an announcement.
On May 9, 2025, MannKind Corporation and its Chief Medical Officer, Burkhard Blank, agreed on his transition from the role of executive officer, with a formal separation agreement established on May 14, 2025. Mr. Blank will continue as a non-executive employee until August 1, 2025, and will receive salary continuation, a special bonus, and COBRA premium reimbursements post-separation, while his equity awards remain eligible for vesting during his employment.
The most recent analyst rating on (MNKD) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on MannKind stock, see the MNKD Stock Forecast page.
Spark’s Take on MNKD Stock
According to Spark, TipRanks’ AI Analyst, MNKD is a Neutral.
MannKind’s stock score reflects a mix of strong revenue growth and profitability, tempered by significant balance sheet risks and a relatively high valuation. The positive sentiment from the earnings call boosts the score, highlighting growth in key areas and strategic partnerships. However, technical indicators suggest caution, and high leverage could pose challenges if growth expectations are not met.
To see Spark’s full report on MNKD stock, click here.
More about MannKind
MannKind Corporation operates in the biopharmaceutical industry, focusing on the development and commercialization of therapeutic products for patients with diseases such as diabetes.
Average Trading Volume: 2,055,090
Technical Sentiment Signal: Sell
Current Market Cap: $1.43B
Learn more about MNKD stock on TipRanks’ Stock Analysis page.